Latest

People

In 2016 consumers will use their mobile phones to spend a total of 620 billion dollars and analysts expect this number to grow to over 1 trillion dollars by 2020. Hoping to capitalize on consumers preference for convenient transactions new payment technologies such as peer to peer payments, crypto currencies and digital wallets have seen rapid growth. In this special report, Corporate Profile® delves into the future of cashless technology with Shlomi Cohen the CEO of OTI (On Track Innovations www.otiglobal.com), a company which hopes to further change the way consumers pay with wearable payment devices.

The Changing Face of Transgender Surgery

December 14, 2015 // 0 Comments

Over the past few years the general public has become increasingly educated about the transgender community due to TV stars like Laverne Cox and Caitlyn Jenner talking openly about their experiences. Although the public is captivated by their stories, the arduous process that goes into a full transformation remains largely unknown. In this special report, host Annamaria Stewart (@AnnamariaChen) discusses the changing face of transgender surgery with world-renowned facial plastic surgeon Doctor Jeffrey Spiegel who’s specialty, facial feminization surgery, is changing the landscape for the transgender community. Join the conversation by using #transformingfaces

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

This series is part of the Huffington Post Outspeak Network.

Music: Infados by Kevin MacLeod is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/…)
Source: http://incompetech.com/music/royalty-
Artist: http://incompetech.com/

The Boston Marathon is an event touted as one of the most difficult marathon courses, due to it’s 26 mile hilly terrain; so would you believe someone actually ran the Boston Marathon 4 times…in a row. Would you find it even harder to believe that just 10 years prior that same person struggled with alcohol addiction and weighed in at 320 lbs. Host Annamaria Stewart sits down with David Clark, Ultra Runner and Author of the book Out There: A Story of Ultra Recovery. David talks about addiction, recovery, weight loss, ultra running, and what he calls the Quad Boston.

Out There: A Story of Ultra Recovery is available on Amazon, Barnes & Noble, and iTunes.

To learn more about The Superman Project visit: www.thesupermanproject.org

This episode is currently airing on ClearVISION, an innovative in-airport TV network which features the best entertainment, news, music, and sports programming for travelers.

HAIFA, Israel, May 13, 2015 (GLOBE NEWSWIRE) — Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) agreed with the proposed quality and large-scale manufacturing methods for PLX-PAD cells for use in clinical trials. This agreement is an important milestone for initiation of a Phase I/II study in critical limb ischemia through Japan’s Accelerated Pathway for Regenerative Medicine. The new regulatory pathway could potentially significantly reduce time to market for cell therapies such as PLX cells.

“Pluristem is emerging as an early leader in the industry’s push to enter Japan’s newly established accelerated regulatory pathway. It is our hope that the PDMA will approve our application for a Phase I/II clinical study of PLX cells in critical limb ischemia via the Accelerated Pathway,” stated Pluristem CEO Zami Aberman.

Japan’s Accelerated Pathway for Regenerative Medicine went into effect in November 2014. According to the law, regenerative medicine therapies can receive conditional, time-limited approval for marketing, and be eligible for reimbursement, upon proof of safety and initial proof of efficacy. Safety and effectiveness need to be confirmed within 7 years after the conditional approval.

LabStyle Innovations develops and commercializes patent-pending technologies that provide consumers with laboratory-testing capabilities using smart mobile devices.

LabStyle’s flagship product is Dario™ the world’s first personalized smart meter. Dario combines a compact all in one glucose meter that plugs directly into a smart mobile device with personalized information and community support to make life easier for people with diabetes.

To learn more about LabStyle Innovations and Dario (DRIO) visit: www.mydario.com

Heat Biologics is a clinical-stage company focused on developing its proprietary “ImPACT”​ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers. Heat Biologics CEO Jeffrey Wolf talks about the company’s ImPACT Therapy and two clinical trials.

To learn more about Heat Biologics visit:
www.heatbio.com

Interview with BioShares Founder Paul Yook

February 2, 2015 // 0 Comments

BioShares Founder, Paul Yook, talks about investing in the Biotech sector and his company’s exchange traded funds. To learn more about BioShares visit www.bioshares.com

The Business of Cannabis –
This is Not Your Parent’s High Times
Many of you have grown up as we did in the 60’s, 70’s, 80’s or even 90’s, when cannabis was commonly referred to as marijuana, maryjane or simply pot. It was associated with Woodstock, Bob Marley, Cheech and Chong, High Times Magazine, and Fast Times at Ridgemont High. Perhaps you may even remember an earlier time in which cannabis was propagandized and demonized, as in the 1936 movie Reefer Madness, a movie in which young teenagers are lured into purchasing marijuana from a couple living in sin and then through a gateway and ultimately down a dark path that leads to addiction, dark crimes, insanity, and even death. Well, as you all know now, the times they are a changin’, and cannabis has now been approved for medical use in over 25 states in the US, and legalized for recreational use in the states of Colorado, Washington, Oregon and Alaska. And it won’t stop there, as proposed legislative changes are taking place nearly every day.
There are a few things that make this industry very fascinating. First of all, of course, is the potential size of the market and industry. Secondly, from a legal perspective, there are unique issues related to the interplay and contradiction between Federal and State law. Thirdly, everywhere we go and whatever financial conferences we attend these days, there seems to be a buzz (pardon the pun) and excitement related to companies associated with this space. And lastly, for now, from a medical use perspective, we have never seen a medical product that is administered without regard to a particular dose, as in “take 2 of these and call me in the morning” or “take 1 every 6 hours for 7 days straight”. It is an anomaly.

Today, there is a burgeoning cannabis industry that some have referred to as “The Green Rush”. It is a growing tide spreading across the US, which in some ways harkens back to the end of prohibition or the way that the legalization of gay marriage has recently swept across many states of our nation. Perhaps more appropriately the issue of whether cannabis-related companies should or can be publicly listed and traded is more akin to the gambling industry, where federal and state laws are not in concert. A recent article published by the Washington Post cites to a report released by Greenwave Advisors, which it refers to as a “comprehensive research and financial analysis for the emerging legalized cannabis industry”. The article goes on to state that “…legal cannabis could be an industry with revenues of $35 billion by 2020 if cannabis is legalized at the federal level”. To put it further in perspective, this $35 billion figure represents more annual revenue than the NFL (currently $10 billion), and is roughly on par with current revenues for the newspaper publishing industry ($38 billion) and the confectionary industry ($34 billion). Thus, we are obviously talking about a potentially very big industry.

The historical uses of cannabis are well documented and many: cannabis has been used for medicine, food, fuel, paper, rope, maps, bricks, oil, paint, furniture and much more. In today’s market, in the states where cannabis has been legalized for recreational use, the primary focus of the market has become threefold, broken down into producers (or growers), processors (or labelers), and retailers. The secondary focus has become the many industries that have developed or are developing around those entities, such as real estate, agriculture, lighting, tourism, technology, research and development, e-commerce, banking and security (to name just a few).

Now once the foundation is set, combine the need and desire of entrepreneurs to raise money to fund their businesses or ideas in this space and you create a perfect storm. It is the interplay of the emerging business, fundraising and regulatory oversight which this Report is concerned. One of our primary focuses will be on companies considering ownership by individuals or entities outside of a small group in the legalized jurisdictions and will range to companies either considering to go public or that may have already crossed the divide and are public, listed and trading on the US capital markets (whether on a national securities exchange on the over-the-counter markets).

We have humbly set out to create a report that is intended to be a central place where readers can gather synthesized information about the regulatory state, development and emerging trends of this growing industry.

1 2 3